Post
Moderna stock jumped 130% following a successful human trial for its skin cancer vaccine. The treatment proved effective even for late-stage melanoma patients.
2mo
102 Likes5 Dislikes10 Reposts1 Comments
?
Moderna stock jumped 130% following a successful human trial for its skin cancer vaccine. The treatment proved effective even for late-stage melanoma patients.
2mo
Moderna stock jumped 130% following a successful human trial for its skin cancer vaccine. The treatment proved effective even for late-stage melanoma patients.
2mo
No comments yet. Be the first!
Comments
No comments yet. Be the first!